Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)

N/AApproved For MarketingNCT05544032

Incyte Corporation

Overview

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.

Study Type

EXPANDED_ACCESS

Conditions

Chronic Graft Vs. Host Disease

Interventions

axatilimabDRUG

Treatment with axatilimab includes receiving intravenous (IV) doses of axatilimab every 2 weeks

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: \- Exclusion Criteria: \-

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.